ArticleBiomarker research2013
Beyond malignancy: the role of carbohydrate antigen 125 in heart failure.
Article in Biomarker research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Carbohydrate antigen 125 and clinical outcomes in heart failure: systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- From Tumor Marker to Congestion Indicator: The Expanding Role of CA-125 in Heart Failure and Beyond.Health science reports · 2026Article
- Antigen carbohydrate 125 as a prognostic biomarker in patients with stable chronic heart failure.Cardiovascular diagnosis and therapy · 2025Article
- Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.Life (Basel, Switzerland) · 2025Review
- The Value of Ischemic Cardiac Biomarkers to Predict Spontaneous Breathing Trial or Extubation Failure: A Systematic Review.Journal of clinical medicine · 2024Review
- Carbohydrate Antigen 125 (CA 125): A Novel Biomarker in Acute Heart Failure.Diagnostics (Basel, Switzerland) · 2024Review
- The significance of elevated tumor markers among patients with interstitial lung diseases.Scientific reports · 2022Article
- Recent Advances in Electrochemical Aptasensors for Detection of Biomarkers.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Biomakers in Chronic Chagas Cardiomyopathy.Microorganisms · 2022Article
- Tumor marker response to SARS-CoV-2 infection among patients with cancer.Cancer medicine · 2022Article
- Carbohydrate antigen 125 in heart failure: congestive kidneys or beyond?European heart journal. Acute cardiovascular care · 2021Article
- The role of carbohydrate antigen 125 in COVID-19.Medical hypotheses · 2021Article
- Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure.Cardiac failure review · 2021Review
- Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbohydrate antigen 125 (CA-125), traditionally a tumor marker for screening, diagnosis, and monitoring in ovarian malignancy, had recently been shown increasing evidence and more extensively recognized/explored as a novel surrogate of heart failure (HF). The exact mechanisms underlying the pathophysiologic link between elevated serum CA-125 concentration and HF may be multi-factorial, with both mechanical and inflammatory process including numerous potential cytokines involved. Accumulating data had consistently indicated its diagnostic and prognostic role in HF patients in various clinical settings, however, there is limited clinical information regarding the incremental value or head-to-head comparison of such marker to other well-established HF markers. In this brief review, we aimed to discuss the biosynthesis, and potential insights of underlying pathophysiologies associated with CA-125 secretion in the scenarios of cardiac structural/functional alterations and HF, and further explored its current usage and roles in several recent reports.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.